| Literature DB >> 34886882 |
Elena V Sazonova1, Svetlana V Petrichuk2, Gelina S Kopeina3, Boris Zhivotovsky4,5.
Abstract
Although the phenomenon of mitotic catastrophe was first described more than 80 years ago, only recently has this term been used to explain a mechanism of cell death linked to delayed mitosis. Several mechanisms have been suggested for mitotic catastrophe development and cell fate. Depending on molecular perturbations, mitotic catastrophe can end in three types of cell death, namely apoptosis, necrosis, or autophagy. Moreover, mitotic catastrophe can be associated with different types of cell aging, the development of which negatively affects tumor elimination and, consequently, reduces the therapeutic effect. The effective triggering of mitotic catastrophe in clinical practice requires induction of DNA damage as well as inhibition of the molecular pathways that regulate cell cycle arrest and DNA repair. Here we discuss various methods to detect mitotic catastrophe, the mechanisms of its development, and the attempts to use this phenomenon in cancer treatment.Entities:
Keywords: Cancer; Cell death; DNA damage; Mitotic catastrophe; Senescence
Mesh:
Year: 2021 PMID: 34886882 PMCID: PMC8656038 DOI: 10.1186/s13062-021-00313-7
Source DB: PubMed Journal: Biol Direct ISSN: 1745-6150 Impact factor: 4.540
Fig. 1Sources of mitotic catastrophe induction and its outcomes (for details, see the text)
Antitumor agents that promote mitotic catastrophe: potential applications and clinical trials
| Inhibitor | Mechanism of action | Tumor types for treatment | Potential applications and clinical trials |
|---|---|---|---|
| ATR inhibitor AZD6738 | ATR blockade leads to destruction of inhibited replication forks with the formation of breaks in the replicated sister chromatids that can be fused by deletions and aberrant chromosomal translocations | Renal cell carcinoma, urothelial carcinoma, all pancreatic cancers, endometrial cancer | Phase 2 clinical trial: AZD6738 alone and in combination with the PARP-inhibitor olaparib (NCT03682289) [ |
| DNA-PK inhibitor NU7026 | Increased polyploidy and mitotic catastrophe after low dose irradiation Negative changes in the NHEJ system in a cell-cycle-dependent manner | Cervical cancer | Preclinical study [ |
| Non-small cell lung cancer | Preclinical study [ | ||
| DNA-PK inhibitor M3814 | Block repair of radiation-induced double-stranded breaks and promote p53-dependent mitotic catastrophe | Ovarian cancer | Preclinical study [ |
| Fibrosarcoma and lung cancer | Preclinical study [ | ||
| DNA-PK inhibitor AZD7648 | This inhibitor in combination with the PARP inhibitor olaparib, doxorubicin, or radiotherapy causes prolonged arrest of the cell cycle in the G2/M transition, accumulation of micronuclei, and chromosomal aberrations that are indicative of mitotic catastrophe | Ovarian cancer | Preclinical study [ |
| HER2 + , HR + and HER2-negative, triple-negative breast cancer | Phase 1–2 clinical trial (NCT03907969) [ | ||
| HPV-negative head and neck cancer squamous carcinoma | Preclinical study [ | ||
Mps1/TTK kinase inhibitor CFI-402257 | Disrupt chromosome segregation and block metaphase | Advanced/metastatic HER2-negative breast cancer | Phase 1b clinical trial in combination with paclitaxel (NCT03568422) [ |
Fig. 2Representative images of morphological changes after induction of mitotic catastrophe were received using classical fluorescent confocal microscopy or imaging flow cytometry. A The ovarian carcinoma Caov-4 cells and the lung adenocarcinoma U1810 cells were treated with colcemid 10 ng/mL, a chemotherapeutic agent that depolymerizes microtubules, for 48 h. Cells were grown, treated, fixed in 4% paraformaldehyde, and stained with MitoTracker Red FM and DAPI directly on coverslips. Mitotic catastrophe development was evaluated by analysis of nuclear morphology using a 63 × /1.4 oil objective lens of a LSM 780 confocal laser scanning microscope (Zeiss). After the colcemid treatment of the cells the multi- and micronucleation were detected. B The ovarian carcinoma Caov-4 cells were treated with colcemid 10 ng/mL for 48 h. After incubation, the cells were collected by trypsin–EDTA and transferred to conditioned medium. The cells were centrifuged and washed twice with cold phosphate-buffered saline. Then, the cells (2.0 × 105) were resuspended in PBS and DAPI was added to the sample and incubated in the dark at 4 °C for 15 min. After incubation, the cells were analyzed by imaging flow cytometry with the ImageStream Mark II - AMNIS (Millipore Merck, Germany). After the colcemid treatment of Caov-4 cells the multinucleation was detected